Literature DB >> 8335681

Nuclear magnetic resonance spectroscopy of plasma to distinguish between malignant and benign diseases causing jaundice and cholestasis.

P A Pasanen1, R Kauppinen, M J Eskelinen, K P Partanen, P H Pikkarainen, E M Alhava.   

Abstract

The sera of 51 patients with malignant (n = 25) and benign (n = 26) hepatopancreatobiliary disorders were analysed by 1H magnetic resonance spectroscopy (NMR) in order to distinguish between malignant and benign diseases causing jaundice and/or cholestasis. Macromolecular linewidths were determined both manually and automatically with a computed analysis, and both methylene (CH2) and methyl (CH3) resonances were evaluated. The mean linewidth of the CH3 peak was significantly narrower in the patients with malignant disease than in the patients with benign disease both in the manual and computed analyses, but no significant differences in the CH2 peak were detected. Diagnostic sensitivity and specificity of the CH3 peak determined in the computed analysis were 92% and 27% respectively. In the light of the current study, it seems obvious that because overlap between benign and malignant groups was too great, 1H NMR spectroscopy of plasma is not of practical value in distinguishing between benign and malignant causes of jaundice and/or cholestasis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335681     DOI: 10.1007/bf01372726

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  13 in total

1.  Lack of efficacy of water-suppressed proton nuclear magnetic resonance spectroscopy of plasma for the detection of malignant tumors.

Authors:  P Okunieff; A Zietman; J Kahn; S Singer; L J Neuringer; R A Levine; F E Evans
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

2.  Proton nuclear magnetic resonance spectroscopy of plasma from healthy subjects and patients with cancer.

Authors:  T Engan; J Krane; O Klepp; S Kvinnsland
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

3.  Detection of malignant tumors: water-suppressed proton nuclear magnetic resonance spectroscopy of plasma.

Authors:  T L Dowd; B A Kaplan; R K Gupta; P Aisen
Journal:  Magn Reson Med       Date:  1987-10       Impact factor: 4.668

4.  Effect of triglyceride levels on methyl and methylene envelope line widths in proton nuclear magnetic resonance spectroscopy of human plasma.

Authors: 
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

5.  Assessment of proton nuclear magnetic resonance spectroscopy for detection of malignancy.

Authors:  P Wilding; M B Senior; T Inubushi; M L Ludwick
Journal:  Clin Chem       Date:  1988-03       Impact factor: 8.327

6.  Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma.

Authors:  E T Fossel; J M Carr; J McDonagh
Journal:  N Engl J Med       Date:  1986-11-27       Impact factor: 91.245

7.  Detection of malignant tumours by multivariate analysis of proton magnetic resonance spectra of serum.

Authors:  E Sletten; O M Kvalheim; S Kruse; M Farstad; O Søreide
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

8.  Detection of tumours with nuclear magnetic resonance spectroscopy of plasma.

Authors:  S Berger; K H Pflüger; W A Etzel; J Fischer
Journal:  Eur J Cancer Clin Oncol       Date:  1989-03

9.  1H and 13C nuclear magnetic resonance studies of plasma from patients with primary intracranial neoplasms.

Authors:  J Peeling; G Sutherland; K Marat; E Tomchuk; E Bock
Journal:  J Neurosurg       Date:  1988-06       Impact factor: 5.115

10.  Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.

Authors:  P A Pasanen; M Eskelinen; K Partanen; P Pikkarainen; I Penttilä; E Alhava
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.